Cardiovascular Outcomes Trials in Diabetes: The Truth, the Whole

Truth, and Nothing But the Truth

Program Goals

The Growing Diabetes Pandemic

Approved Antidiabetic Medications

Cardiovascular benefits to tighter HbA1c control?

Outcomes of Better Glycemic Control in T2D: UKPDS and Post-

UKPDS

Should Hyperglycemia in Diabetes Be Treated Aggressively?

DCCT/EDIC: Intensive Diabetes Therapy in T1D

Counseling a Patient With Newly Diagnosed T2D

Sulfonylureas

Safety of Sulfonylureas

Safety of Sulfonylureas (cont)

The CAROLINA Study: Phase 3 Results

Rosiglitazone Data Reanalyzed

Results of a Reevaluation of Cardiovascular Outcomes in the

RECORD Trial

Thiazolidinediones

Pioglitazone: The PROactive Study

Guidance for Industry: Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat T2D

Impact of FDA Guidance: December 2008

Incretin-Based Drugs

Incretin-Based Drugs (cont)

Warnings and Precautions

SGLT-2 Inhibitors

SGLT-2 Inhibitors (cont)

SAVOR-TIMI 53 trial

Take-Home Messages

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)